124 related articles for article (PubMed ID: 38702799)
1. Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients.
Watanabe T; Ototake Y; Akita A; Suzuki M; Kanaoka M; Tamura J; Saigusa Y; Yamaguchi Y
Arthritis Res Ther; 2024 May; 26(1):93. PubMed ID: 38702799
[TBL] [Abstract][Full Text] [Related]
2. Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis.
Meridor K; Sagy I; Molad Y
Mod Rheumatol; 2022 Oct; 32(6):1086-1093. PubMed ID: 34927207
[TBL] [Abstract][Full Text] [Related]
3. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of anti-Ro52-kDa/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: Data from a French cohort, a systematic review and meta-analysis.
Martel ME; Leurs A; Launay D; Behal H; Chepy A; Collet A; Sanges S; Hachulla E; Dubucquoi S; Dauchet L; Sobanski V
Autoimmun Rev; 2024 May; 23(5):103536. PubMed ID: 38555075
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody profile in a cohort of Algerian patients with systemic sclerosis.
Tahiat A; Allam I; Abdessemed A; Mellal Y; Nebbab R; Ladjouze-Rezig A; Djidjik R
Ann Biol Clin (Paris); 2020 Apr; 78(2):126-133. PubMed ID: 32175889
[TBL] [Abstract][Full Text] [Related]
6. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study.
Wangkaew S; Euathrongchit J; Wattanawittawas P; Kasitanon N; Louthrenoo W
Mod Rheumatol; 2016 Jul; 26(4):588-93. PubMed ID: 26561397
[TBL] [Abstract][Full Text] [Related]
7. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
8. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival.
Wodkowski M; Hudson M; Proudman S; Walker J; Stevens W; Nikpour M; Assassi S; Mayes MD; Wang M; Baron M; Fritzler MJ; ; ;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S131-5. PubMed ID: 26315678
[TBL] [Abstract][Full Text] [Related]
9. Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.
Pauling JD; Salazar G; Lu H; Betteridge ZE; Assassi S; Mayes MD; McHugh NJ
Rheumatology (Oxford); 2018 Apr; 57(4):712-717. PubMed ID: 29294089
[TBL] [Abstract][Full Text] [Related]
10. Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center.
Li H; Zhang X; Yu L; Shang J; Fan J; Feng X; Zhang R; Ren J; Guo Q; Duan X
Front Med (Lausanne); 2022; 9():1061738. PubMed ID: 36561716
[TBL] [Abstract][Full Text] [Related]
11. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
12. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.
Chang WS; Schollum J; White DH; Solanki KK
Clin Rheumatol; 2015 Nov; 34(11):1921-7. PubMed ID: 26022620
[TBL] [Abstract][Full Text] [Related]
16. Clinical and serological hallmarks of systemic sclerosis overlap syndromes.
Pakozdi A; Nihtyanova S; Moinzadeh P; Ong VH; Black CM; Denton CP
J Rheumatol; 2011 Nov; 38(11):2406-9. PubMed ID: 21844148
[TBL] [Abstract][Full Text] [Related]
17. Scleroderma-specific autoantibodies: Should they be included in the diagnostic work-up for Sjögren's syndrome?
Marketos N; Koulouri V; Piperi EP; Georgaki ME; Nikitakis NG; Mavragani CP
Semin Arthritis Rheum; 2022 Aug; 55():152026. PubMed ID: 35623241
[TBL] [Abstract][Full Text] [Related]
18. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
[TBL] [Abstract][Full Text] [Related]
19. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies.
Landon-Cardinal O; Baril-Dionne A; Hoa S; Meyer A; Leclair V; Bourré-Tessier J; Mansour AM; Zarka F; Makhzoum JP; Nehme J; Rich E; Goulet JR; Grodzicky T; Koenig M; Joyal F; Richard I; Hudson M; Targoff I; Satoh M; Fritzler MJ; Troyanov Y; Senécal JL
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32892170
[TBL] [Abstract][Full Text] [Related]
20. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
